JW Bioscience invests in Singapore's molecular diagnostic firm One BioMed

Pulse 입력 2021. 1. 18. 14:21
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

[Photo provided by JW Bioscience]

South Korea’s JW Life Science said on Monday its subsidiary JW Bioscience and One BioMed Pte. Ltd., a Singapore-based biotech firm dedicated to molecular diagnostics, have entered into a strategic partnership after an equity investment for cooperation in new diagnostic assays and reagents.

Under their agreement, JW Bioscience acquired a 3.4 percent stake in One BioMed and rights to distribution of One BioMed’s point of care testing (POCT) products across Korea.

One BioMed will use the funding to develop next-generation diagnostic assays and reagents.

One BioMed was established in 2015 as a spinoff from the Agency for Science, Technology and Research (A*STAR), Singapore’s lead government agency.

One BioMed has an advanced platform for the development of POCT equipment, spanning from silicon optical device sensing technology to sample preparation, gene extraction, target amplification, and signal measurement.

The equity investment will also allow JW Bioscience to diversify its business to molecular diagnostics from its existing immunochemistry and clinical chemistry diagnostics.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]

Copyright© 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지

이 기사에 대해 어떻게 생각하시나요?